Tenax Therapeutics, Inc. (“Tenax” or the “Company”) investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Tenax Therapeutics, Inc. (NASDAQ: TENX), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Tenax Therapeutics, Inc. on August 10, 2026.

If you lost money on Tenax Therapeutics, Inc. securities, share your Tenax Therapeutics, Inc. loss information with the firm to learn about potentially pursuing a claim to recover your losses.

Tenax Therapeutics, Inc. investigation at a glance

  • Date of disclosure: August 10, 2026
  • Share price decline: $12.06 per share, or 89.77%
  • Closing price: $1.38 on August 10, 2026

What happened?

On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 “did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score.“

On this news, Tenax’s stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.

“Tenax Therapeutics, Inc. shares dropped 89.77% after it was disclosed on August 10, 2026 that Tenax’s Phase 3 LEVEL trial of TNX-103 had failed to meet its primary endpoint of improved 6-minute walk distance versus placebo or its key secondary endpoint of improved Kansas City Cardiomyopathy Questionnaire total symptom score. Our investigation will look at whether investors had complete and accurate information before that disclosure,” said Frank R. Cruz of The Law Offices of Frank R. Cruz.

What should Tenax Therapeutics, Inc. investors do now?

The Law Offices of Frank R. Cruz is investigating potential claims on behalf of Tenax Therapeutics, Inc. investors. Investors who lost money can visit the Tenax Therapeutics, Inc. investigation page, email info@frankcruzlaw.com, or call 310-914-5007.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

Questions and answers about the Tenax Therapeutics, Inc. investigation

Who is eligible? Investors who purchased Tenax Therapeutics, Inc. securities and suffered losses may have claims, and can contact the firm to find out whether the Tenax Therapeutics, Inc. investigation affects them.

What does a securities fraud investigation involve? In the Tenax Therapeutics, Inc. investigation, The Law Offices of Frank R. Cruz is examining whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.

Is there a lawsuit? This release announces an investigation by The Law Offices of Frank R. Cruz, not a lawsuit. If a securities class action is later filed against Tenax Therapeutics, Inc., investors may be able to seek appointment as lead plaintiff.

How are attorneys’ fees handled? The Law Offices of Frank R. Cruz works on contingency, so Tenax Therapeutics, Inc. investors pay no attorneys’ fees up front. Any attorneys’ fees and litigation expenses come only from a recovery, if there is one, and require court approval.

Information for whistleblowers

Anyone with non-public information about Tenax Therapeutics, Inc. should consider their options to assist the investigation or participate in the SEC Whistleblower Program. The program allows whistleblowers who provide original information leading to a successful SEC enforcement action to receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Frank R. Cruz at 310-914-5007 or email info@frankcruzlaw.com.

About The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.

Prior results do not guarantee a similar outcome.

Related links

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Media gallery

About The Author
Business Wire